Among them, the Nox1/Nox4 inhibitor GKT137831 (Figure 4) is the most advanced compound and has already reached phase II of clinical trials for the treatment of type 1 diabetes mellitus [140]. This evidence concerns the gene NOX4 and diabetes mellitus.